Community Portal

A place for Clinicians and Healthcare Suppliers to share knowledge and learn more about THE CLINICIAN EXCHANGE



Provided by: Medscape

Do Your Patients Believe in Medical Conspiracy Theories?

Published: Wed, 16 Aug 2017 06:22:47 EDT
More than half of Americans say that big business and government is, in some way, conspiring against the health of the people.
Medscape Reader Polls

Enhanced RN Role in Behavioral Health Care

Published: Wed, 16 Aug 2017 12:00:00 EDT
Utilizing RNs in behavioral health care may help reduce healthcare costs and improve patient care.
Nursing Economics

A Workshop on Breaking Bad News for Anesthesiology Residents

Published: Wed, 16 Aug 2017 12:00:00 EDT
Breaking bad news to patients and relatives is always a stressful task. Can an education intervention modeled on 'The GRIEV_ING Death Notification Protocol' help prepare residents for the task?
BMC Anesthesiology

DAA Combination for Elderly Patients With Chronic Hepatitis C

Published: Wed, 16 Aug 2017 12:00:00 EDT
This study aimed to assess the cost-effectiveness of direct-acting antivirals for the treatment of chronic hepatitis C in elderly patients. Which patients should be considered for treatment?
Liver International
Displaying results 1-4 (of 20)
 1 - 2 - 3 - 4 - 5 


China’s Zai Lab files for $115M Nasdaq IPO to take Tesaro, Bristol-Myers cancer drugs through late-phase trials

Published: Wed, 16 Aug 2017 09:57:32 +0000
Zai Lab has filed to raise up to $115 million in a Nasdaq IPO. The biotech plans to use the money to hustle cancer drugs licensed from Bristol-Myers Squibb and Tesaro through late-phase trials in its home country of China.

China cancer biotech Antengene gets off $21M series A

Published: Wed, 16 Aug 2017 09:30:49 +0000
Antengene has gained a healthy $21 million series A just a few months after setting up a deal with Celgene.

Novartis, Lilly-backed Cavion poaches Teva executive as R&D head

Published: Tue, 15 Aug 2017 13:33:52 +0000
Spyridon "Spyros" Papapetropoulos has joined the ranks of small, neurological disease-focused biotech Cavion as EVP of research and development and CMO.

Lexicon builds case for Sanofi-partnered diabetes pill

Published: Tue, 15 Aug 2017 13:07:23 +0000
Lexicon Pharmaceuticals has bolstered the case for its Sanofi-partnered diabetes pill. The latest update means Lexicon now has data from two phase 3 trials showing the effect of the SGLT1-SGLT2 inhibitor sotagliflozin on A1C in patients with Type 1 diabetes is sustained over 52 weeks.
Displaying results 1-4 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy